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Abstract
Background: Photosensitizer based fluorescence imaging and spectroscopy is fast becoming a
promising approach for cancer detection. The purpose of this study was to examine the use of the
photosensitizer chlorin e6 (Ce6) formulated in polyvinylpyrrolidone (PVP) as a potential exogenous
fluorophore for fluorescence imaging and spectroscopic detection of human cancer tissue
xenografted in preclinical models as well as in a patient.
Methods: Fluorescence imaging was performed on MGH human bladder tumor xenografted on
both the chick chorioallantoic membrane (CAM) and the murine model using a fluorescence
endoscopy imaging system. In addition, fiber optic based fluorescence spectroscopy was performed
on tumors and various normal organs in the same mice to validate the macroscopic images. In one
patient, fluorescence imaging was performed on angiosarcoma lesions and normal skin in
conjunction with fluorescence spectroscopy to validate Ce6-PVP induced fluorescence visual
assessment of the lesions.
Results: Margins of tumor xenografts in the CAM model were clearly outlined under fluorescence
imaging. Ce6-PVP-induced fluorescence imaging yielded a specificity of 83% on the CAM model. In
mice, fluorescence intensity of Ce6-PVP was higher in bladder tumor compared to adjacent muscle
and normal bladder. Clinical results confirmed that fluorescence imaging clearly captured the
fluorescence of Ce6-PVP in angiosarcoma lesions and good correlation was found between
fluorescence imaging and spectral measurement in the patient.
Conclusion: Combination of Ce6-PVP induced fluorescence imaging and spectroscopy could
allow for optical detection and discrimination between cancer and the surrounding normal tissues.
Ce6-PVP seems to be a promising fluorophore for fluorescence diagnosis of cancer.
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Background
As with most cancers, early diagnosis is critical to achieve
favorable prognosis. Currently, random surveillance biop-
sies are the existing gold standard for the identification of
lesions in pre-neoplastic conditions. However this
method is prone to sampling error, time-consuming, sub-
jective and cost-inefficient. A diagnostic method that
could provide rapid, automated classification of cancer
lesions would increase the efficiency and comprehensive-
ness of malignancy screening and surveillance procedures.
A variety of optical techniques have recently been utilized
for the diagnostic study of cancerous tissue. These include
fluorescence spectroscopy [1], Raman spectroscopy [2],
light scattering spectroscopy [3], and Fourier-transform
infrared spectroscopy [4]. These optical spectroscopic
techniques are capable of providing biochemical and
morphological information in short integration times,
which can be used for automated diagnosis of intact tis-
sue. However, in order to be useful as a comprehensive
screening procedure, the optical technique must allow
rapid real time imaging of a large area of tissue rather than
point by point measurement, such that suspicious regions
could be identified accurately and biopsied for his-
topathologic correlation [5].
With the advent of molecular probes, imaging methods
such as ultrasound, microCT (Computed Tomography),
microMRI (Magnetic Resonance Imaging), and microPET
(Positron Emission Tomography) can be conducted not
only to visualize gross anatomical structures, but also to
visualize substructures of cells and monitor molecule
dynamics [6]. Imaging of endogenous or exogenous fluor-
ochromes has several important advantages over other
optical approaches for tumor imaging. This imaging tech-
nique relies on fluorochrome induced fluorescence,
reflectance, absorption or bioluminescence as the source
of contrast, while imaging systems can be based on diffuse
optical tomography, surface-weighted imaging, phase-
array detection, intensified matrix detector and charged-
coupled device camera detection, confocal endomicros-
copy, multiphoton imaging, or microscopic imaging with
intravital microscopy [7,8]. Fluorescence ratio imaging is
a method widely used for optical diagnosis of cancer after
administration of a photosensitizer [9]. Enhanced con-
trast between tumor and adjacent normal tissue can be
obtained based on calculating the ratio between red inten-
sity of the photosensitizer (600–700 nm) over the blue/
green intensity of the back-scattered excitation light or tis-
sue autofluorescence (450–550 nm). Many investigations
have confirmed good agreement with the histopathologi-
cal extent of the tumor, implying that this technique can
be applied as a useful tool for indicating tumor boundary
[10].
A number of fluorochromes such as fluorescein, toluidine
blue, cyanine dyes and indocyanine green have been
described with variable stabilities, quantum efficiencies,
and ease of synthesis. However, most of the fluoro-
chromes are not tumor specific and are rapidly eliminated
from the organism. Chemically and endogenously synthe-
sized fluorochromes such as porphyrin based photosensi-
tizers have properties that may be utilized both
experimentally and clinically. Porphyrins have been
known to naturally localize in malignant tissue where
they emit light when irradiated at certain wavelengths,
providing a means to detect tumor by the location of its
fluorescence. However, one of the major limitation is its
slow clearance from tissues and long period of skin pho-
totoxicity. Moreover, the porphyrin's core absorbs wave-
lengths of light too short for optimal penetration in tissue.
As such, by reducing a pyrrole double bond on the por-
phyrin periphery, a chlorin core compound can be gener-
ated with a high absorption at longer wavelengths of 660
– 670 nm that can penetrate deeper in human tissue than
those of porphyrins. Of particular interest among the eval-
uated chlorins is the naturally occurring chlorin e6 (Ce6)
[11]. Ce6 has improved efficacy and has decreased side
effects compared to first generation photosensitizers from
hematoporphyrin derivatives. Due to the importance of
Ce6's characteristic fluorescence properties, there is a need
to identify new formulations that are stable, exhibit ease
in manufacturing and selectively deliver the photosensi-
tizer to target tissue in an efficient manner. Hence, we
have investigated the use of Ce6 in combination with the
polymer polyvinylpyrrolidone (Ce6-PVP). Polyvinylpyr-
rolidone is one of the most important excipient used in
modern pharmaceutical technology. We have previously
described the selective localization and photodynamic
activity of Ce6-PVP in nasopharyngeal and lung carci-
noma models that provided rationale for its use as a ther-
apeutic agent for photodynamic therapy [12,13]. By
employing a chick chorioallantoic membrane model,
Ce6-PVP was shown to selective accumulate in bladder
tumors xenografts and had a faster clearance from normal
CAM when administered topically compared to system-
atic administration [14]. The uptake ratio of Ce6-PVP was
found to have a 2-fold increase across the CAM when
compared to that of Ce6, indicating that PVP was able to
facilitate diffusion of Ce6 across the membrane [15]. Fur-
thermore, Ce6-PVP had less in vivo systemic phototoxic
effect compared to Ce6 alone after light irradiation in
photodynamic therapy in mice bearing tumors [16].
Using a chemical fluorescence extraction technique and
cuvette-based spectrofluorimetry, our data demonstrated
that the distribution of Ce6-PVP drug were much lower in
normal organs such liver, spleen, kidney, brain, heart and
lung compared to Ce6 delivered using dimethylsulfoxide
(DMSO) [17]. We also postulated that the extent of tumor
necrosis post Ce6-PVP mediated photodynamic therapyBMC Medical Imaging 2009, 9:1 http://www.biomedcentral.com/1471-2342/9/1
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(PDT) was dependent on the plasma concentration of
Ce6-PVP, implying a vascular mediated cell death mecha-
nism [18].
In this study, we have evaluated the usefulness of Ce6-PVP
to accurately define the margin of the tumor from its nor-
mal adjacent tissue in the chick choriallantoic membrane
(CAM) tumor model. We also presented visual informa-
tion on Ce6-PVP induced fluorescence in tumor and gross
anatomical structure of normal organ of a murine model.
Fluorescence spectroscopy measurements were also per-
formed to characterize emission spectra from these tissue
samples as well as to corroborate results from fluorescence
images. Finally, a pilot trial was carried out to validate the
use of Ce6-PVP as a clinically relevant diagnostic photo-
sensitizer using both imaging and spectroscopy modality
for differentiation of normal and tumor tissue in a patient.
Methods
Photosensitizer
The formulation of Ce6-PVP, also known as Fotolon or
Photolon was supplied by HAEMATO-science GmbH,
Germany. It is a co-lyophilisate of Ce6 sodium salt and
PVP (a pharmaceutical grade polymer, molecular mass ≈
12,000 g/mol) in a 1:1 mass ratio [19].
Cell culture
MGH (European Collection of Cell Cultures), a poorly
differentiated human bladder carcinoma cells were grown
as a monolayer in RPMI-1640 medium supplemented
with 10% fetal bovine serum, 1% non-essential amino
acids (Gibco, USA), 1% sodium pyruvate (Gibco, USA),
100 units mL-1 penicillin-streptomycin (Gibco, USA) and
incubated at 37°C, 95% humidity and 5% CO2.
Chick choriallantoic membrane tumor model
Fertilized chicken eggs were incubated at 37°C in a
humidified atmosphere inside a hatching incubator
equipped with an automatic rotator (Octagon 20, Brinsea,
Somerset, UK). At embryo age (EA) 7, a window of about
1.5 cm was opened in the eggshell to detach the shell
membrane from the developing CAM. Then, the window
was sealed with sterilized parafilm to avoid contamina-
tion and the eggs were returned to the static incubator for
further incubation until the day of experiment. On EA 9,
approximately 5–10 × 106 MGH cells were inoculated on
the CAM. The window of the eggs were resealed with ster-
ile parafilm and returned to the static incubator. Grafted
cells were allowed to grow on the CAM for up to 5 days.
On EA 14, Ce6-PVP was dissolved in 0.9% sodium chlo-
ride to constitute a stock solution of 1 mg/mL. The stock
solution was further diluted to obtain a volume of 500 μL
containing a dose of 1 mg/kg body weight of the chick's
embryo. The photosensitizer was applied on the entire
surface of the CAM and left to incubate for 30 min. The
window was resealed to avoid evaporation of the drug
solution from the CAM. After 30 min incubation, macro-
scopic fluorescence imaging was performed at 0.5, 1, 2, 3,
4, and 5 h post drug administration using a commercially
available fluorescence endoscopic system (Karl Storz, Tut-
tlingen, Germany). A modified xenon short arc lamp (D –
Light system in blue light mode, Karl Storz) filtered by a
band pass filter (380 – 450 nm) was used for excitation of
photosensitizer in tissue. Fluorescence was captured via a
sensitive CCD camera (Tricam SL PAL, Karl Storz)
attached to an endoscope integrated with a long pass filter
(cut-off wavelength 470 nm). This observation LP filter of
the endoscope only minimally transmits the diffuse back-
scattering excitation light with a peak at 450 nm (blue
light), while has a transmission of over 98% in the 470 –
800 nm range. The red channel registered the photosensi-
tizer's fluorescence and the blue channel captured the dif-
fusely back-scattered excitation light. A short exposure of
the surface of tissue to the excitation light (10 s) was per-
formed to avoid excessive photobleaching effects. White
light imaging was used to correlate the boundaries of
tumors and organs. All procedures involving preparation
and administration of the photosensitizer were conducted
under low ambient lighting.
Murine tumor model
A total of 10 Balb/c athymic nude mice and C57 mice, 6–
8 weeks of age, weighing an average of 24 g were obtained
from the Animal Resource Centre, Western Australia and
Centre for Animal Resources, National University of Sin-
gapore respectively. Before inoculation, the cell layer was
washed with phosphate-buffered saline, trypsinized, and
counted using a hemocytometer. Approximately 3.0 × 106
MGH cells suspended in 150 μl of Hanks' Balanced Salt
Solution (Gibco, USA) were injected subcutaneously into
the lower flanks of Balb/c athymic nude mice. The ani-
mals were used for experiments when the tumors meas-
ured around 7 – 10 mm in diameter. This ensured that the
tumor sizes were kept consistent to minimize variations
due to the degree of vascularization of the implants. Mice
were injected with a dose of 5 mg/kg of Ce6-PVP via tail
vein injection. At 1, 3 and 6 h, mice were sacrificed and
the skin overlaying the tumor was carefully removed to
expose the tumor and normal peritumoral muscle for flu-
orescence imaging. C57 mice were used for imaging and
spectroscopy of normal organs. All procedures were
approved by the Institutional Animal Care and Use Com-
mittee, SingHealth, Singapore, in accordance with inter-
national standards.
Spectroscopic measurement using fiber optics-based 
fluorescence spectrometer
The spectral measurement was performed on mice sacri-
ficed at 1 and 3 h post Ce6-PVP administration. A fiber
optics-based fluorescence spectrometer (Spex SkinSkan,BMC Medical Imaging 2009, 9:1 http://www.biomedcentral.com/1471-2342/9/1
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JY Inc., Edison, NJ, USA) was used for the measurement of
fluorescence intensity of Ce6-PVP. A monochromator
with a 150-W Xenon lamp was used as the excitation light
source. The excitation light (400 nm) was guided to illu-
minate samples by one arm of a Y-type quartz fiber bun-
dle, and the emission fluorescence was collected by
another arm of the fiber bundle, guided to another motor-
controlled monochromator. The resulting emission spec-
tra were recorded from 650 to 750 nm, in 1 nm incre-
ments, collected using the DataMax version 2.20
(Instruments SA, Inc.) software package. The optical fiber
tip was placed on the measuring sites and fluorescence
intensity spectra were measured. After each measurement,
the optical fiber tip was carefully cleaned to remove the
possible remaining drug on the tip.
Human subject
After informed consent, 1 patient with histologically
proven angiosarcoma was recruited in this pilot case
study. One tumor was located on the scalp, and 2 at the
temperomandibular joint. These tumors had been previ-
ously treated with Ce6-PVP photodynamic therapy. The
patient was intravenously administered with Ce6-PVP
with a dose of 2.0 mg/kg for repeated photodynamic ther-
apy on existing and a new angiosarcoma lesion on the
scalp and face. Before light irradiation, fluorescence imag-
ing and spectroscopy were performed on 3 angiosarcoma
lesions, normal scalp and skin at 1 and 3 h post drug
administration. The patient had to remain in subdued
light throughout the imaging period. This study was
approved by the National Cancer Centre Singapore's Insti-
tutional Review Board.
Data analysis
To evaluate the quality of discrimination between healthy
and tumor tissues of the fluorescence images in the CAM
model, the red to blue ratio algorithm was applied. Such
algorithm is independent of the geometries of excitation/
collection of signals and the power of excitation during
the fluorescence imaging process. The sensitivity and the
specificity of the classifier were calculated using the
receiver-operator characteristics (ROC) curves by plotting
the fluorescence intensity of tumor against the fluores-
cence intensity of normal CAM tissue using the GraphPad
software (GraphPad Prism™ Version 4.03, San Diego,
USA). The ROC curve illustrates the trade-off between sen-
sitivity and specificity for the different threshold of red to
blue ratios to distinguish healthy from tumor tissue. Next,
the cut-off value corresponding to the highest combined
sensitivity and specificity was chosen and evaluated. For
fluorescence spectroscopy, the emission spectra data pre-
sented in the results are the absolute fluorescence intensi-
ties of the tissues after pre-processed using Fourier
transformation to decrease noise levels and normalizing
the spectra to baseline at 700 nm. The normalization pro-
cedure significantly reduced the within-class variances.
Spectral data from the various organs and tissues were
analyzed to determine spectral line shape and the peak
fluorescence intensities at region of 660 – 690 nm.
Results
Fluorescence imaging of bladder tumor xenografts on the 
CAM model
Fluorescence was not observed from the tumors under
blue light illumination before drug administration. After
topical administration of Ce6-PVP, an intense red fluores-
cence in the bladder tumor xenografts was observed, sug-
gesting selective localization in the malignant cells.
Fluorescence in the normal CAM tissue was lower com-
pared to fluorescence in the tumor tissue, suggesting
either a lower uptake or faster clearance rate from normal
tissue of the CAM (Figure 1). The fluorescence retention
from 1 to 5 h post topical administration of Ce6-PVP in
bladder tumor xenografts on CAM was tabulated using
the red to blue ratio algorithm and fitted into a ROC curve
to validate the ability of Ce6-PVP to discriminate tumor
from adjacent normal CAM membrane. By applying a cut-
off value to these ratios as a diagnostic criterion, it allows
the generation of sensitivity and specificity values to dis-
tinguish tumor from healthy CAM. A cut-off red to blue
ratio of > 1.08 gives the highest combined sensitivity and
specificity were 70.8% (95% CI 48.9% to 87.4%) and
83.3% (95% CI 62.6% to 95.3%) respectively (Figure 2).
Raising the value to > 1.33 gives the sensitivity and specif-
icity values of 62.5% (95% CI 40.59% to 81.20%) and
91.2% (95% CI 73.0% to 99.0%) respectively.
Fluorescence imaging of tumor and normal organs in mice 
models
Fluorescence imaging was performed on the bladder
tumor xenograft, peritumoral muscle, and normal blad-
der at 1 and 3 h post intravenous injection of Ce6-PVP in
mice (Figure 3). Representative fluorescence images of
skin and various internal organs taken at 1 h post Ce6-PVP
administration are presented in Figure 4. Overall, tumor
fluorescence was observed to be more intense compared
to the adjacent peritumoral muscle. Fluorescence inten-
sity in bladder tumor was also higher compare to fluores-
cence of normal bladder tissues. The internal organs were
also found to yield substantial fluorescence especially the
gall bladder, liver, stomach, small and gastrointestinal
tracts. Minimal fluorescence was observed in the heart
and spleen. The fluorescence intensity in muscle, skin,
lung, liver, and bladder dropped at 3 h post drug admin-
istration. There was little or no fluorescence remaining in
heart and spleen. In contrast, the tumors showed sus-
tained fluorescence intensity at 3 h post drug administra-
tion. By 6 h post drug administration, minimal
fluorescence was detected in the gastrointestinal tract,
liver and bladder (Figure 5).BMC Medical Imaging 2009, 9:1 http://www.biomedcentral.com/1471-2342/9/1
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Fluorescence imaging of MGH human bladder tumor xenografted on the CAM model Figure 1
Fluorescence imaging of MGH human bladder tumor xenografted on the CAM model. (A) White light image of 
the tumor before drug administration, (B) Ce6-PVP induced red fluorescence in tumor imaged under blue light illumination at 
3 h post drug administration. Minimal fluorescence was observed in the adjacent normal CAM. (C) By displaying the fluores-
cent image in a pseudo color using simple image processing technique, a clear discrimination of the tumor border can be visu-
alized.
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In vivo fiber optic spectrofluorometric measurement
Typical fluorescence emission spectra from tumor, adja-
cent peritumoral muscle and normal bladder after i.v.
administration of Ce6-PVP are shown in Figure 6. In gen-
eral, the peak fluorescence intensities of tumor were
higher than those of normal sites. The greatest intensity
occurred in the region between 660 – 670 nm. When the
spectra were normalized to baseline value, changes in
peak intensity became evident. The line-shape differences
were predominantly due to increased Ce6-PVP accumula-
tion of tumor in the red region (emission peak at 665
nm). Fluorescence emission spectra of skin, heart, lung,
gall bladder, liver, spleen, kidney and gastrointestinal
tract are shown in Figure 7. Except for the gall bladder, all
other organs showed a decreased of fluorescence emission
of Ce6-PVP at 3 h compared to 1 h post drug administra-
tion. Essentially, fluorescence images that showed greater
red fluorescence intensity had visibly higher spectral peak,
thus suggesting that that the macroscopic fluorescence
imaging were reproducible.
Fluorescence imaging and spectrofluorometric 
measurement in a patient
Fluorescence imaging and spectroscopy carried out on 3
tumors in an angiosarcoma patient showed that the
tumors developed maximum fluorescence emission
intensity at 3 h post Ce6-PVP administration (Figure 8).
No observable variations were found for the intensity of
the fluorescence between tumors. The fluorescence kinet-
ics study findings from this consistent to those of our ear-
lier results [17]. Spectra from tumor areas show a clear
distinct Ce6-PVP induced fluorescence spectrum that dis-
criminate between the tumor and normal skin, with
A scatter plot comparing the fluorescence intensity in tumor and the adjacent normal CAM tissue was compiled from 1 – 5 h  post topical drug administration Figure 2
A scatter plot comparing the fluorescence intensity in tumor and the adjacent normal CAM tissue was com-
piled from 1 – 5 h post topical drug administration. The points on the scatter plot are normalized individual measure-
ments from 24 eggs. The dotted line is the cut-off fluorescence intensity threshold derived from the ROC curve to classify 
tumor from normal tissue with a sensitivity and specificity of 70.8% (95% CI 48.9% to 87.4%) and 83.3% (95% CI 62.6% to 
95.3%) respectively.
Tumor Adjacent normal tissue
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
R
e
d
 
t
o
 
b
l
u
e
 
i
n
t
e
n
s
i
t
y
 
r
a
t
i
o
> 1.082BMC Medical Imaging 2009, 9:1 http://www.biomedcentral.com/1471-2342/9/1
Page 7 of 13
(page number not for citation purposes)
Macroscopic fluorescence imaging in bladder tumor xenografts and normal bladder at 1 h and 3 h post-intravenous administra- tion of 5 mg/kg Ce6-PVP Figure 3
Macroscopic fluorescence imaging in bladder tumor xenografts and normal bladder at 1 h and 3 h post-intrave-
nous administration of 5 mg/kg Ce6-PVP. Ce6-PVP induced fluorescence can be characterized by red fluorescence. At 
both time points, higher fluorescence intensity was observed in the tumor compared to the adjacent muscle and normal blad-
der of the mice.
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Macroscopic white light and fluorescence imaging in skin, heart, lung, gall bladder, liver, spleen, kidney and gastrointestinal tract  at 1 h post-intravenous administration of 5.0 mg/kg Ce6-PVP Figure 4
Macroscopic white light and fluorescence imaging in skin, heart, lung, gall bladder, liver, spleen, kidney and 
gastrointestinal tract at 1 h post-intravenous administration of 5.0 mg/kg Ce6-PVP.
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tumor showing higher fluorescence emission intensity
compared to normal tissue.
Discussion
Fluorescence imaging approaches are increasingly being
used as a medical diagnostic procedure to assess tissue
malignancy over conventional methods because they do
Macroscopic white light (A, C, E) and fluorescence (B, D, F) imaging in normal bladder, liver, gall bladder, and gastrointestinal  tract at 6 h post-intravenous administration of 5.0 mg/kg Ce6-PVP Figure 5
Macroscopic white light (A, C, E) and fluorescence (B, D, F) imaging in normal bladder, liver, gall bladder, and 
gastrointestinal tract at 6 h post-intravenous administration of 5.0 mg/kg Ce6-PVP.
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not use potentially harmful ionizing radiation [20]. In sit-
uations where discrimination of suspicious lesion is clin-
ically problematic, fluorescence imaging may provide
added advantage in demarcating abnormal tissue. The
development of photosensitizer based fluorescence imag-
ing is hindered by problems such as skin photosensitivity,
poor selectivity of the photosensitizer, and formulation
issues. For these reasons, Ce6 was formulated with PVP to
address these issues. Formulations using biocompatible
polymers such as PVP are increasingly being used in the
pharmaceutical industry for enhancing drug solubility
and bioavailability. Complexation of Ce6 with PVP was
found to prevent Ce6 aggregation in aqueous media and
led to an enhancement of Ce6 fluorescence quantum
yield, while keeping the quantum yield of the intersystem
crossing essentially unchanged [21]. In this study we have
further examined the potential clinical use of Ce6-PVP in
cancer imaging and diagnosis. We first tested out the fea-
sibility of this photosensitizer as an exogenous fluoro-
phore on the CAM tumor model. We were able to observe
the red fluorescence emitted by the tumor tissue excited
using a filtered xenon lamp excitation, which enabled
clear determination of the tumor margin. The sensitivity
of Ce6-PVP was more than 80%, however, the specificity
remained low. We have recently reported that the new for-
mulation of Ce6-PVP (> 95% purity level of active Ce6)
demonstrated a higher sensitivity (98%) and specificity
(82%) on the CAM model [15].
Results from the CAM experiments have provided the
motivation to examine Ce6-PVP fluorescence distribution
in bladder tumor xenograft as well as in various normal
organs of a murine model. Macroscopic fluorescence
imaging showed that there was considerable distinction in
the localization of fluorescence in tumor compared to
other organs that could enable discrimination between
tumor and normal organs. Organs of elimination and
detoxification such as skin, gall bladder and gastrointesti-
nal tracts were characterized by high photosensitizer accu-
mulation efficiency. In contrast, all other normal organs
such as muscle and bladder had much lower photosensi-
tizer accumulation at 1 h post drug administration. Blood
vessels growing on the tumor can also be observed
because they contrast with the fluorescence of the tumors.
At 3 – 6 h post drug administration, a decrease of fluores-
cence intensity became evident on all normal organs, con-
firming that Ce6-PVP has fast clearance rate from normal
organs. In some instances, we have observed variability of
fluorescence intensity on the surface tissue such as stom-
ach and lung. This is possibly attributed to the variations
of the tissue optical properties of the organs given by their
color, density and composition.
The key issue in fluorescence imaging is that the emitted
fluorescence intensity measured from a tissue surface is
not necessarily proportional to the fluorophore concen-
tration because the light is altered by the tissue's intrinsic
Comparison of emission spectra of bladder tumor xenograft, normal bladder and muscle of the murine model at 1 and 3 h post  administration of Ce6-PVP using 400 nm excitation Figure 6
Comparison of emission spectra of bladder tumor xenograft, normal bladder and muscle of the murine model 
at 1 and 3 h post administration of Ce6-PVP using 400 nm excitation. The spectral signatures showed a peak at the 
wavelength 665 – 670 nm in tumor while the fluorescence intensity of normal bladder and muscle is weaker than that of the 
tumor tissue.
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absorption and scattering properties. Hence we have
employed the utility of spectrometric point fluorescence
detection as a complementary technique. Spectra meas-
urements were carried out at 1 and 3 h post drug admin-
istration to correlate the tumor intensity ratios obtained
with fluorescence imaging to the tumor fluorescence spec-
tral signal of the tissue. All the macroscopic fluorescence
images correlated well to the spectra measurement. The
Ce6-PVP induced spectra emission after normalization
demonstrated a good separation to differentiate malig-
nant tumors from normal tissues. Besides measuring
physical parameters such as concentration of photosensi-
tizer and tissue properties, this method can potentially
improve the assessment of cancer location and its extent
within the local-regional area. While fluorescence point
spectroscopy studies are promising, it has several draw-
backs as a screening tool as it can only interrogate a small
volume of tissue (typically, 0.5 – 1 mm3) directly beneath
the probe tip. Point measurements inevitably involve a
degree of random sampling, which may not allow identi-
fication of early stage disease [22]. Hence, the combina-
tion techniques of fluorescence imaging and spectroscopy
have been proven in good agreement with the actual
Comparison of emission spectra in the 650 – 700 nm region using 400 nm excitation in various normal organs at 1 and 3 h post  Ce6-PVP administration Figure 7
Comparison of emission spectra in the 650 – 700 nm region using 400 nm excitation in various normal organs 
at 1 and 3 h post Ce6-PVP administration. Except for skin and gall bladder, it is evident that the emission spectra of nor-
mal organs were lower compared to the emission spectra of tumor.
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tumor boundary found by histopathological mapping
and early stage of disease [23,24].
Recently, we have reported photodynamic therapy – acti-
vated immune response against distant untreated
tumours in recurrent angiosarcoma [25] and preferential
accumulation of Ce6-PVP in angiosarcoma compared to
normal skin following intravenous administration in 3
patients [17]. High dose PDT carried out at a high fluence
rate resulted in local control of the disease for up to a year;
however, the disease recurred and PDT had to be repeated
[26]. During the repeat PDT session, we measured the flu-
orescence of 3 different lesions using fluorescence imag-
ing followed by spectroscopy. The results confirmed that
fluorescence imaging clearly captures the fluorescence in
angiosarcoma and good correlation was found between
fluorescence imaging and spectral measurement in the
patient. This is in agreement with other reports, that fluo-
rescence ratio imaging in combination with relative spec-
tral measurement of the photosensitizer might be a viable
method for the optical diagnosis of cancer [27]. Further-
more, in vivo and real-time determination of the time
course of photosensitizer's fluorescence could potentially
be a crucial pre-irradiation screening tool to determine the
exact location and extent of the tumor before photody-
namic therapy.
Fluorescence imaging and spectrofluorometric measurement of fluorescence emission in angiosarcoma lesion and surrounding  normal skin on the scalp at 1 h and 3 h post-intravenous administration of 2.0 mg/kg Ce6-PVP Figure 8
Fluorescence imaging and spectrofluorometric measurement of fluorescence emission in angiosarcoma lesion 
and surrounding normal skin on the scalp at 1 h and 3 h post-intravenous administration of 2.0 mg/kg Ce6-
PVP.
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Conclusion
It is shown that Ce6-PVP has a rapid accumulation in the
tumor, and a relatively short half-life in normal organs.
When excited by blue light, Ce6-PVP accumulating cells
can be visualized and located in the tissue by virtue of its
fluorescence. The main advantage of Ce6-PVP induced
fluorescence imaging is its increased tumor selectivity
with the ability to clearly define the tumor margin. Com-
bination of Ce6-PVP induced fluorescence imaging and
spectroscopy could allow detection and discrimination
between cancer and the surrounding normal tissues.
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